NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Pallarès, Victor, Hoyos, Montserrat, Chillón, M. Carmen, Barragán, Eva, Conde, M. Isabel Prieto, Llop, Marta, Céspedes, María Virtudes, Nomdedeu, Josep F., Brunet, Salut, Sanz, Miguel Ángel, González-Díaz, Marcos, Sierra, Jorge, Casanova, Isolda, Mangues, Ramon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652681/
https://ncbi.nlm.nih.gov/pubmed/29100287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18537
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller